Diabetes firm brings in additional USD 10m for phase III trial

Vtv Therapeutics has raised around USD 35m over the summer, proceeds that have gone to an imminent phase III trial of a type 1 diabetes treatment candidate.

Photo: Malina Petr/AP/Ritzau Scanpix

After another financing round has been completed, US-based Vtv Therapeutics has secured an additional USD 10m funding, this time from investment firm Cinpax, the biotech firm reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs